Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The combined company will thus produce devices across cardiovascular, diabetes, vision and neuromodulation markets.
Miles D White, chairman and chief executive officer, Abbott, says, “The combined business will have a powerful pipeline ready to deliver next-generation medical technologies, and offer improved efficiencies for health care systems around the world.”
Michael T Rousseau, St Jude Medical president and chief executive officer, says, “Our combined scale will expand the global reach, competitiveness and impact of our medical device innovation for physicians and hospitals.”
New medical devices planned for release across diverse markets by the combined company include:
- St Jude Medical’s EnSite Precision next-generation cardiac mapping system, designed to allow physicians to visualise and navigate catheters in the heart during ablation procedures;
- MultiPoint pacing technology using quadripolar technology, which is designed to provide additional options for cardiac resynchronisation therapy patients who are not responsive to other pacing options;
- Proclaim Elite recharge-free spinal cord stimulation system; and
- Prodigy chronic pain system—a device used for treating chronic pain which is MRI safe, upgradeable, featuring St Jude Medical’s proprietary Burst technology.
- Abbott’s FreeStyle Libre, a sensor-based glucose monitoring system;
- Tecnis Symfony, a continuous range of vision intraocular lens for the treatment of people with cataracts; and
- Absorb, a bioresorbable coronary stent.
